MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide Following Patent Expiry.

▴ MSN Laboratories
MSN Laboratories today announced the launch of SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO).

Hyderabad, 15th April 2026 - MSN Laboratories today announced the launch of SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). This milestone reinforces the company’s commitment to expanding access to advanced therapies for chronic metabolic diseases, including type 2 diabetes. SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration.

 

Since 20th March 2026, the market has seen a surge of new entrants. In this evolving landscape, SEMABEST stands apart with its strong backward integration across in-house USDMF-grade API and formulation. The Pen device is also made in India complying with global regulatory standards. SEMABEST represents a significant step forward in making complex peptide therapies more accessible, affordable, and scalable for Indian patients.

 

“The product has demonstrated bioequivalence to the reference (innovator) drug, with its performance further validated through Phase III clinical studies conducted in direct comparison. The results showed comparable reduction in HbA1c levels, along with similar outcomes across key parameters including fasting plasma glucose (FPG), postprandial glucose (PPG) & weight loss. SEMABEST also exhibited a comparable safety profile, reinforcing its reliability as an effective therapeutic option.” said Dr Kamini Desai, Head – Medical Affairs, MSN Laboratories.

 

India is home to nearly 90 million people living with diabetes, with a significant proportion remaining undiagnosed or inadequately managed. The disease is often associated with serious complications, including cardiovascular disorders, kidney failure, and vision impairment, placing a substantial burden on patients and the healthcare system.

 

“The launch of SEMABEST marks a defining step in our journey to make next-generation metabolic therapies more accessible and affordable. As the burden of diabetes continues to rise, we remain focused on delivering high-quality, innovative solutions that can make a meaningful difference in patients’ lives,” said Dr. MSN Reddy, Founder & CMD, MSN Laboratories.

 

“MSN brings over a decade of expertise in complex peptide development, with its journey in this domain dating back to 2016 with the filing of its first USDMF for icatibant. Since then, the company has established a strong regulatory and scientific foundation, with 12 USDMFs for peptides and 6 US ANDAs for peptide formulations, supported by a broader portfolio of 560+ USDMFs and 400+ bioequivalent formulations globally. Leveraging its integrated R&D infrastructure and large-scale manufacturing capabilities, MSN is well positioned to ensure consistent supply, quality, and accessibility of SEMABEST across India.” said Bharat Reddy, Executive Director, MSN Laboratories.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026